Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice relating to the proposed sale of 2,000 shares of Common Stock (consisting of 1,580 and 420 restricted shares) with trade/reporting dates of 03/11/2026. The filing shows a listed market NASDAQ and a filing/report date of 05/26/2026.
EXPO files a Form 144 notice reporting proposed sales of restricted common stock.
The filing lists three restricted stock lots of 594, 568 and 510 shares with grant dates 03/11/2022, 03/11/2026 and 03/12/2021
Exponent Inc. Group Vice President Richard Reiss reported an open-market sale of 1,672 shares of Common Stock on May 19, 2026 at an average price of $58.6496 per share.
After this transaction, he directly holds 2,288 shares of Exponent common stock.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related share sales. On May 15, 2026, she exercised options for a total of 5,606 shares of common stock at strike prices of $29.05 and $25.405 per share, converting derivative awards into regular shares.
On the same date, she sold 4,194 shares of common stock in open-market transactions at an average price of $54.0595 per share. A footnote states these sales were made to cover the option exercise price and taxes, indicating a routine liquidity event rather than a purely discretionary sale. After these transactions, Corrigan directly owns 105,218 shares of Exponent common stock.
EXPO affiliate submitted a Form 144 notice to sell 4,194 shares of Common Stock via exercise of stock options on 05/15/2026. The filing also lists 10b5-1 sales by Catherine Corrigan in the prior three months: 3,909, 3,912, and 3,920 shares with gross proceeds reported.
Exponent Inc: Kayne Anderson Rudnick Investment Management, LLC reported beneficial ownership of 3,886,546 shares of Exponent Inc, representing 7.9% of the class as of 03/31/2026. The filing breaks down voting and dispositive power: sole voting power 2,839,655, shared voting power 1,042,670, sole dispositive power 2,843,876, and shared dispositive power 1,042,670.
Exponent Inc.’s Group Vice President Joseph Rakow reported an open-market sale of company stock. On May 13, 2026, he sold 2,945 shares of Exponent common stock at an average price of $54.6601 per share. Following this transaction, his directly held common stock position reported in this filing was 0 shares.
Exponent Inc. Group Vice President Joseph Sala reported an open-market sale of Common Stock. On May 13, 2026, he sold 2,066 shares at $56.66 per share. Following this transaction, the filing shows Sala directly holding 0 shares of Exponent common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of Common Stock of EXPO with a filing date of 05/13/2026. The filing lists two blocks of restricted stock dated 03/11/2026 and 03/11/2022.
Morgan Stanley Smith Barney LLC submitted a Form 144 relating to EXPO Common stock. The filing, dated 05/13/2026, lists proposed sales of Common shares identified as restricted stock including 986 shares issued 03/11/2026 and 1,080 shares issued 03/11/2022. The filing names NASDAQ as the market.